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Bulleted statements: 
What’s already known about this topic? 
 In patients with systemic sclerosis (SSc) many autoantibodies are detected 
 Some autoantibodies in SSc are likely to be involved in the pathogenesis of the 
disease 
 Studies have reported complement activation in SSc 
 Studies investigating antibodies against C1q, frequently detected in systemic lupus 
erythematosus, have not been performed in SSc 
What does this study add? 
 Anti-C1q antibodies are frequently detected in patients with SSc 
 Anti-C1q antibody level is the most important risk factor for the presence of lung 
fibrosis 
 
Abbreviations: CEN, centromere; CIC, circulating immune complexes; dc, diffuse 
cutaneous; lc, limited cutaneous; NC, normal control; RA, rheumatoid arthritis; RNA pol III, 
RNA polymerase III; Scl-70, scleroderma 70; SSc, systemic sclerosis; SLE, systemic lupus 
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Part of this work was presented as a poster, Annual Congress of EULAR, 8-11 June, 
London, 2016 (full citation: Liaskos C, Rentouli S, Simopoulou T, et alAB0613 Anti-C1q 
Autoantibodies Are Frequently Detected in Patients with Systemic Sclerosis and Lung 
FibrosisAnnals of the Rheumatic Diseases 2016;75 (supp2):1114. 
 
Summary 
Background: Anti-C1q autoantibodies  (autoAbs) are associated with systemic lupus 
erythematosus (SLE) but their presence in other rheumatic diseases has not been 
adequately investigated. 
 
Objective: We aim to assessanti-C1q autoAbs and circulating immune complexes (CICs) in 
systemic sclerosis (SSc).    
 
Methods: One hundred twenty four patients with SSc (106 females; median age 59.4 years, 
range 25-81.4; 75(60.5%) with limited cutaneous SSc[lcSSc], and 49(39.5%) with diffuse 
cutaneous SSc[dcSSc]), were studied. Twenty-five patients with Sjögren’s syndrome (SjS), 
29 with rheumatoid arthritis (RA), and 38 patients with systemic lupus erythematosus (SLE) 
and 53 healthy controls (NC) were also included.  ELISAs with high and low salt buffers the 
former allowing  IgGFc binding to C1q, the latter not allowing IgGFc binding and anti-C1q Ab 
binding to C1q were used to measure anti-C1q Abs and CICs.  
 
Results:Anti-C1q Abs were present in20/124 (16.1%) SSc patients [5 had high levels (>80 
RU/mL) and 10 patients (50%) had moderate levels (40-80 RU/mL)] compared to 1/25 (4%) 
SjS, 1/29 (3.4%) RA patients (p<0.05, for all) and 3/53 (5.7%) NCs (p<0.01). Anti-C1q Abs 










This article is protected by copyright. All rights reserved. 
female SSc patients (p=0.005); this association remaining after multivariate regression 
analysis . Anti-C1q Ab level was the first most important factor in predicting the presence of 
pulmonary fibrosis and the second in predicting pulmonary arterial hypertension. Fourteen 
SSc patients (11.3%) had CICs.  
 
Conclusions:Anti-C1q autoAbs were frequently detected in patients with SSc and their high 
levels predict the co-occurrence of pulmonary fibrosis or pulmonary arterial hypertension.  
Introduction 
Systemic sclerosis (SSc)is characterized by extensive fibrosis, microvasculopathy including 
vasospastic episodes (Raynaud’s phenomenon, RP)and fibrointimal proliferation, and the 
presence of many autoantibodies (autoAbs).  The pathogenesis of the disease is 
incompletely understood 1, 2. Microvasculopathy, as detected by nailfoldcapillaroscopy, and 
autoAbsappear years before skin fibrosis. Many autoAbs are detected in SSc, including 
disease-specific autoAbs, such as anti-topoisomerase I (anti-Topo I, formerly anti-Scl70) and 
anticentromere (anti-CEN)Abs which are independent predictors for the progression of RP to 
SSc3-5.  Many autoAbs in SSc are likely to be pathogenic, since they promote inflammation 
and fibrosis6, 7. These include anti-endothelial cell 8, 9, anti-fibroblast 10, anti-matrix 
metalloproteinase-3 11, anti-fibrillin-1 12, anti-angiotensin II type 1 receptor 13, and anti-
platelet-derived growth factor receptor antibodies14, 15. The presence of many autoAbsmight 
suggest activation of the classical pathway of complement. Indeed, studies in the eighties 
reported complement activation in SSc, as suggested by elevated plasma levels of 
complement fragment C3d and C4d16. Activated complement (C5b-9)and complement 
receptor for C5a (C5aR) were detected in the microvasculature of skin biopsies from patients 
with SSc17.Also, reduced function of complement(C1,C4,C3) was detected in SSc18, and 
reduced serum levels of C3 and/or C4 was detected in 14% of patients with SSc and were 
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Anti-C1q autoAbsare frequently detected in systemic lupus erythematosus (SLE) and are 
strongly associated with lupus nephritis20-24.  Two SLE studies with small numbers of SSc 
patients used as disease controls showed either a small frequency and increase20or no 
increased frequency25 of anti-C1q autoAbs in SSc. It should be mentioned that the 
methodology of anti-C1q Ab detection faces a technical problem to distinguish between 
IgGFc (of immune complexes) binding to C1q and anti-C1 Ab binding to C1q.  To clarify 
these observations and issues,we assessed the clinical significance of anti-C1q autoAbs in a 
large cohort of SSc patients.  
 
Material and Methods 
Patients and Controls 
One hundred and twenty four patients with SSc (106 females; median age 59.4 years, range 
25-81.4; 75 (60.5%) with limited cutaneous SSc[lcSSc], and 49 (39.5%) with diffuse 
cutaneous SSc[dcSSc]), were studied. All patients fulfilled the American College of 
Rheumatology criteria for SSc, and attended the Out-patient Systemic Sclerosis Clinic of the 
Department of Rheumatology and Clinical Immunology, at the University General Hospital of 
Larissa, in central Greece4, 26, 27.  Demographic, laboratory and clinical data were collected 
for all patients (Table 1). Pulmonary arterial hypertension (PAH)was confirmed by right heart 
catheterization (RHC) and pulmonary fibrosis was diagnosed with high resolution CTscan. 
Conventional treatment regimens included low-dose steroids (<7.5 mg/day) plus 
azathioprine or methotrexate. All SSc patients had anti-nuclear antibodies by indirect 
immunofluorescence. Twenty five patients with Sjögren’s syndrome (SjS), 29 with 
rheumatoid arthritis (RA), and 38 patients with systemic lupus erythematosus (SLE) served 
as disease controls, and 53healthy individualsused as normal controls (NCs). A written 










This article is protected by copyright. All rights reserved. 
The protocol was approved by the Local Ethical Committee of the University General 
Hospital of Larissa, University of Thessaly, Larissa, Greece and all procedures were in 
accordance with the revised Declaration of Helsinki. 
 
SSc-related AutoAb testing 
All SSc sera are tested at diagnosis for ANA by indirect immunofluorescence, and for anti-
centromere, anti-Topo I and anti-RNA polymerase III (RNA pol III) Abs. To ensure 
consistency, aliquots stored at -80 °C were tested at the same time for anti-C1q Abs by an 
ELISA and for anti-Topo I, anti-CEN and anti-RNA pol III Abs by an SSc profile line 
immunoassay (Euroimmun, Lubeck, Germany)4. This profile testing would enable correlation 
analysis between anti-C1q Abs and SSc-specific antibodies and was performed in 
51SScpatients.  
 
Anti-C1q Ab testing by ELISA 
Anti-C1q antibodies were measured by enzyme-linked immunosorbent assay (ELISA) 
(QUANTA Lite® IgG anti-C1q, INOVA Diagnostics, Inc. San Diego, CA, USA). Testing was 
performed according to the manufacturer’s instructions. Briefly,serum samples were diluted 
1:10 with high ionic strength buffer that does not allow IgGFc (of circulating immune 
complexes, CIC) binding to C1q of plates, and 100 μLof diluted serum was incubated for 30 
min at 20 °C.Then, microplate wells were washed (x3) and incubated for 30min at 20 °C with 
100 μL of horseradish peroxidase-conjugated anti-human IgG. The plates were washed (x3) 
and incubated for 30 min in the dark with 3,3’,5,5’tetramethylbenzidine (TMB) chromogen. 
The reaction was terminatedwith stop solution (0.344M sulfuric acid) after 15 minutes. The 
absorbance of the samples was read using a microplate reader (BIOTEK, Winnoski, VT, 
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considered positive; 20-40 RU weakly positive; 40-80 RU moderately positive; and >80 RU 
strongly positive, according to the manufacturer's interpretation of results. 
 
Measurement of circulating immune complexes (CICs) by ELISA 
A second ELISAwas used to measure circulating immune complexes (CICs).  Microwell 
plates pre-coated with purified human C1q(as above) were used (Inova). This ELISA with 
low salt concentration permits IgGFc (of CICs) binding, as well as anti-C1q Ab binding to 
C1q of the microplates. CIC-positivity was defined by subtracting high-salt ELISA serum 
sample positivity from low-salt ELISA positivity.  
 
Corresponding data were presented in the form of scatter plots or Ab reactivity in patients 
and controls and VENN diagram, a set of circles each representing the total number of 
patients positive for an autoantibody, to illustrate the relationship between anti-C1q Abs and 
the three major SSc-related autoAbs tested for diagnostic purposes (anti-CEN, anti-Scl-70 
and anti-RNA III pol autoAb) 
 
Statistical analysis  
The required sample size was estimatedusing the statistical software G-power for ANCOVA 
(Fixed effects, main effects and Interactions). Parametric and non-parametric tests were 
used for our study sample description, as appropriate. Univariate and multivariate regression 
analysis was used to study the effect of a battery of parameters on the levels of anti-C1q IgG 
levels.In anticipation for clinical and statistical interactions among the variables under study, 
the multivariate model was reduced to the most logically robust. To determine whether the 
manufacturer’s cut off for anti-C1q antibody levels could be used, we also assessed the cut-
off for the anti-C1q IgG assay by plotting a receiver operator characteristic (ROC) curve 
using the test results of the patients with SSc versus normal or disease controls. A 95% CI 
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analysis to predict the importance of anti-C1q Abs among a bundle of variables in predicting 
pulmonary fibrosis and pulmonary arterial hypertension. Random forest analyses were 
implemented using the “randomForest” package with R. P-values smaller than or equal to 
0.05 were considered significant. The statistical calculations were performed with Graph 
PadPrism Software 5 and R. 
 
Results 
Anti-C1q Ab testing 
We performed a sample size estimation using G-power analysis for the multivariate model.  
Our study required 122 patients (a error probability: 0.05, power;1-β error probability:0.8 and 
degrees of freedom:3)  (supplementary data). To this end, we obtained serum samples from 
124 patients with SSc enrolled in our study.  To assess whether the cut off value of 20 
RU/mL set by the manufacturer applies to our SSc cohort, we performed ROC curve 
analyses (Fig 1).  For a specificity (vs NC) set to 1 (95% CI, 0.89 to 1), cut off value had to 
be determined at 32.5 RU/mL (sensitivity 0.24, 95% CI, 0.15 to 0.36), while for a pre-
determined specificity of 0.97 (95% CI, 0.83 to 1, LR, 7.42) the cut off value for anti-C1q 
positivity had to be set to 31.3 RU/ml. Taking into account that anti-C1q Ab positivity has 
been previously reported to be present in 3-7% of NC, we considered that the desired 
specificity had to be set to > 0.93 (Figure 1).  According to our ROC analyses a 0.94 
specificity (95% CI, 0.79 to 1, LR: 5.02) required a cut off value > 19.45 RU/mL. Thus, we 
concluded that the cut off value for anti-C1q Ab, set at 20 RU from the manufacturer, could 












This article is protected by copyright. All rights reserved. 
Overall, anti-C1q Abs were present in 20/124 (16.1%) SSc patients compared to 1/25 (4%) 
SjS patients, 1/29 (3.4%) RA patients (p<0.05, for all) and 3/53 (5.7%) NCs (p<0.01). The 
frequency of anti-C1q Abs in patients with SLE was within the reported range (13/38, 
34.2%). Amongst the 20 anti-C1q Ab-positive SSc patients, 5 (25%) had high levels (>80 
RU/mL), and 10 patients (50%) had moderate levels (40-80 RU/mL).   
 
Figure 3 shows a VENN diagram depicting anti-C1q Ab positivity and the three most specific 
SSc autoAbs (Anti-Topo, anti-CEN and anti-RNA pol III).  Anti-Topo I, anti-CEN and anti-
RNA pol III autoAbs did not differ between anti-C1q Ab-positive and anti-C1q Ab-negative 
patients (Fig. 3 and Table 1).  
 
Clinical significance of anti-C1q Abs 
Anti-C1q Abs were more frequent in male than female SSc patients (7/18, 38.9% vs 13/106, 
12.3%, p=0.005) (Table 1 and 2, Supplementary Fig 1). The anti-C1q positivity was also 
more frequent in dcSSc than in lcSSc  (12/49, 25% vs 8/75, 10.7%, p=0.049). The presence 
of anti-C1q Abs was associated with pulmonary fibrosis (p=0.023, Table 1). No other 
association was found between the presence of anti-C1q Abs and other clinical features 
(digital ulcers, PAH, arthritis, serositis, gastrointestinal involvement, telangiectasia, 
scleroderma renal crisis, and calcinosis). However, after performing a multiple regression 
analysis, only the effect of the gender persisted (Supplementary Table 2 and Supplementary 
Fig 1 and 2). Prediction analysis showed that the Anti-C1q Ab  level is the first most 
important factor in predicting the presence of pulmonary fibrosis and the second important 
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Prevalence and clinical significance of CICs 
CICsare frequently found in patients with SLE but also in other autoimmune rheumatic 
diseases, including RA. CICs were calculated from the low salt buffer ELISA that 
allows,apart from anti-C1q Ab binding, IgGFc (of CICs) binding to C1q of the microplate 
wells. Overall, 34 (27.4%) SSc patients exhibited positivity with the low salt buffer ELISA, 
and therefore, by subtracting 20 patients with anti-C1q Abs, 14 SSc patients(11.3%) were 
positive for CICs.  No association was found between CICs and demographic, clinical (digital 
ulcers, PAH, pulmonary fibrosis, arthritis, serositis, GI involvement, telangiectasias, 
scleroderma renal crisis, and calcinosis) or immunological (SSc autoAbs, such as anti-Topo 
I, antI-CENP and anti-RNA pol III autoAbs) features (Table 2). 
 
Discussion 
The present study found that anti-C1q Abs are frequently detectedin patients with SSc. 
There are two reports of anti-C1q Abs testing in SLE, which included patients with SSc.  One 
SLE study with 55 SSc patients reported a small increase but low frequency of anti-C1q Abs 
in SSc compared to NCs (5.5% vs 2.1%) 20 and a second SLE study with 20 SSc patients 
reported no difference in the frequency of anti-C1q autoAbs between SSc and NCs (10% vs 
10%) 25.The increased prevalence of anti-C1q Abs in our cohort may relate to the enhanced 
sensitivity of the assay.  As mentioned, the methodology of anti-C1q Ab detection faces a 
technical problemto distinguish between IgGFc (of CICs) binding and anti-C1q Ab binding to 
C1q of the ELISA plate. This problem has been solved by the use of high salt concentration 
in the assay(1 M NaCl) that disrupts the binding of IgGFc to C1q28.   
 
C1q is part of the C1 complex (the other parts being serine proteases C1r and C1s), a 
critical component of classical complement pathway of activation. The activation of the 
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IgG complexed to antigen.  Anti-C1q abs bind to collagen-like tail of C1q29.The anti-C1q 
ELISA by INOVA we utilized, has a high ionic strength buffer to disrupt the binding of IgGFc 
(of immune complexes) to C1q28, 30  and thus detects only anti-C1q Abs.  We also utilized an 
ELISA with low ionic strength buffer to detect both anti-C1q Abs plus IgGFc-C1q binding 
(circulating immune complexes). By using both assays we could measure anti-C1q Abs as 
well as CICs and assess associations of anti-C1q Abs but also associations of CICs.  
 
The diagnostic utility of anti-C1q autoAbs is relatively low since only 5 out of 26 patients 
without SSc-specific anti-CEN, anti-Topo I or anti-RNA pol III autoAbs have anti-C1q 
autoAbs. Nevertheless, our study shows that serum IgGanti-C1q autoAbs are detected in a 
significant percentage of SSc patients; in fact, anti-C1q Abs are equally prevalent with anti-
RNA pol III Abs, which have so far been considered the third most prevalent autoAb in 
patients with SSc. Furthermore, the presence of anti-C1q Abs appears to be more prevalent 
in male patients with SSc. The numbers of male patients in this study is small as expected, 
since the proportion of male patients in SSc large cohorts and registries is 12%-16%31, 32. 
Yet, the association of anti-C1 Abs with male sex stands in multivariate analysis. The 
pathophysiological significance of this association is not clear at present. Of relevance, the 
prognostic value of anti-C1q levels is highlighted by prediction analysis showing that the anti-
C1q Ab level is the first most important factor in predicting the co-occurrence of pulmonary 
fibrosis and the second important factor in predicting pulmonary arterial hypertension. 
Prospective studies must address the significance of this finding, and if such studies are 
proved to be correct, the potential of anti-C1q to be used as clinical biomarker must be 
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It is logical to assume that alterations of the classical pathway of complement relates to 
microvascular injury. Microvascular damage is an early and critical component of SSc. 
Endothelial cell apoptosis in skin biopsies was detected very early in avian scleroderma, and 
in the early inflammatory stage of human SSc33, 34 and was caused by anti-endothelial cell 
antibodies33, 35. Microvascular clinical manifestations of SSc are serious and include digital 
ulcers, resorption of terminal phalanges of digits, PAH, and scleroderma renal crisis. It may 
also contribute to organ fibrosis through hypoxia. Male sex is associated with microvascular 
features in SSc. For instance, male sex is a risk factor for progression of early PAH in SSc36, 
and for early mortality in SSc37, 38 with PAH being the most common cause of death37. Male 
sex is also a risk factor for mortality in patients at risk for PAH39. Nevertheless, the relation of 
male sex with anti-C1q Abs and PAH should be assessed in larger studies. 
 
However, C1q has other functions independent of complement activation. For instance, C1q 
binds to apoptotic cells and increases their clearance by phagocytes (opsonisation)40-42.  
Furthermore, it exerts immunosuppressive effects, as C1q-bound apoptotic cells suppressed 
dendritic cell- and macrophage-mediated Th1 and Th17 proliferation43. Therefore, the 
presence of anti-C1q autoAbs may be related to autoimmunity44, 45and thus may be involved 
in the pathogenesis of SSc. As mentioned, anti-C1q abs bind to collagen-like tail of C1q and 
this likely impairs the removal of apoptotic cells29. Indeed, anti-C1q Abs from lupus nephritis 
patients bind to C1q on early apoptotic cells and significantly reduce phagocytosis of early 
apoptotic cells by macrophages45. This suggests that a defective clearance of apoptotic cells 
may serve as a source of autoantigens in SSc.  Anti-C1q autoAbs from lupus nephritis 
patients also inhibit the deposition of C3c on immune complexes(IC)-C1q(opsonisation of 
ICs) and the binding of opsonized ICs to red blood cells45, thus suggesting another source of 
persisted autoantigens in SSc.Of relevance, we assessed the presence of CICs in our SSc 
cohort, and 14 SSc patients (11.3%) tested positive for CICs.Another means by which anti-
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traps(NETs). NETs, formed by neutrophils on exposure to pathogens, contain nuclear 
chromatin and granule enzymes, to fight pathogens but may also serve as a source of 
autoantigens and promote autoimmunity.  C1q binds to NETs(NET opsonisation) thus 
facilitating their clearance46.  Abs binding to NETs from sera of SLE patients inhibit NETs 
degradation and this impairment correlates with lupus nephritis47.  However, it is not known if 
NET formation is increased in SSc. 
 
In summary, our study found increased frequency of anti-C1q autoAbs and CICs (both 
products of plasma cells) in patients with SSc and particularly in male patients. The 
presence of increased levels of anti-C1q Abs is a predictive factor for the presence of lung 
fibrosis and pulmonary arterial hypertension. Their involvement in the pathogenesis of SSc 
needs further assessments.48-51However, their clinical significance needs to be further 
assessed in multicentre studies with well-defined SSc patients. 
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Legends to the Figures 
Figure 1.ROC for anti-C1q antibodies in SSc patients versus normal controls or SSc 
patients versus pathological controls 
 
Figure 2. Vertical Scatter plot illustration of anti-C1q antibody responses expressed as 
Relative units (RU) in patients with SSc (n=124), Sjögren’s syndrome (n=25), rheumatoid 
arthritis (n=29), systemic lupus erythematosus (n=39) and in 53 normal controls (NC). Solid 
lines in each group express mean RU±SEM. Tests were considered positive when values 
were >20 Relative Units (RU); weak positive in between 20-40 RU; moderately positive in 
between 40-80 RU; and strongly positive >80 RU, according to the manufacturer's 
interpretation of results. 
 
Figure 3.VENN diagram showing concurrent IgG anti-C1q, anti-CEN, anti-Scl-70 and anti-
RNA III pol autoantibody reactivities in 51 patients with SSc patients. 
 
Figure 4. Figure. Random forest variable importance plot highlighting the role of  anti-C1q in 
(A) predicting pulmonary fibrosis (PF) and (B) pulmonary arterial hypertension (PAH). As 
illustrated anti-C1q iAb level s the first most important factor in predicting the development of 
PF and the second (after age) important factor in predicting PAH. 
 
Supplementary Figures  
Supplementary Figure 1. The effect of gender in the anti-C1q antibody levels. 
Supplementary Figure 2. The effect of disease phenotype extension of the anti-C1q 
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Table 1. Clinical and immunological associations between anti-C1q antibody positive and anti-C1q antibody negative patients 
with systemic sclerosis (SSc): Univariate analysis. 
 Total SSc patients 
(n=124) 




Mean age, years (±SD) 













Type of SSc 
Limited/limited cutaneous, n (%) 
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Table 2.Clinical and immunological associations between CIC-C1q positive and CIC-C1q negative patients with systemic sclerosis (SSc). 
 Total SSc patients (n=124) 
 
CIC-C1q (+)SSc(n=34) CIC-C1q (-)SSc(n=90) p value 
Epidemiological 
Mean age, years (±SD) 













Type of SSc 
Limited/limited cutaneous, n (%) 
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Pulmonary fibrosis, n (%) 
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